Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8928897 | 0.82 | CYP3A4 (0.46) | MAPTKMT2ATSHRALDH1A1HPGD | |
| SCHEMBL9526014 | 0.82 | PKM (0.46) | KDM4EALDH1A1HPGDL3MBTL1RXFP1 | |
| SCHEMBL9825968 | 0.82 | MKNK1 (0.41) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL3067240 | 0.81 | SMN1; SMN2 (0.36) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL2027674 | 0.80 | MAPT (0.47) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL11520628 | 0.80 | MAPT (0.41) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL8801741 | 0.79 | MAPT (0.42) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL14419258 | 0.79 | GAA (0.44) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL1371646 | 0.79 | KMT2A (0.42) | MAPTKMT2ATSHRHSD17B10KDM4E | |
| SCHEMBL7670938 | 0.78 | TSHR (0.45) | MAPTKMT2ATSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMA (US) | 2015-02-05 | — | — | US | disclosed |
| US-8853244-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853244-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-8759389-B1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-24 | — | — | US | disclosed |
| US-8399478-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8354439-B2 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| EP-2007757-B1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8188134-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110288095-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110178146-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7915305-B2 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-29 | — | — | US | disclosed |
| US-7829590-B2 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2010-11-09 | — | — | US | disclosed |
| US-20090286840-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-19 | — | — | US | disclosed |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20070238758-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | OTSUKA PHARMACEUTICAL CO., LTD. | 2007-10-11 | — | — | US | disclosed |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-20 | — | — | US | disclosed |
| US-20070105911-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | CHIHIRO MASATOSHI | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238758-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | IL2, IL1RN, SELL | MAPT 4492/4885KMT2A 4083/4885TSHR 724/4885 |
| US-20080045570-A1 | To treat autoimmune, inflammatory, proliferative, hyperproliferative,neurodegenerative or immunologically-mediated diseases; useful for the study of kinases in biological and pathological phenomena; study of intracellular signal transduction pathways mediated by such kinases, and comparative evaluation | MAP3K1, MAP3K20, MAP3K2 | MAPT 775/4885KMT2A 2551/4885TSHR 2079/4885 |
| US-20150038535-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | MAPT 1279/4885KMT2A 784/4885TSHR 2596/4885 |
| US-20070105911-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | IL2, IL1RN, SELL | MAPT 4491/4885KMT2A 4090/4885TSHR 742/4885 |
| US-20110178146-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, ABL1, MAP3K5 | MAPT 1279/4885KMT2A 784/4885TSHR 2596/4885 |
| US-20070219205-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | MAPT 1279/4885KMT2A 784/4885TSHR 2596/4885 |
| US-20110288095-A1 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, ABL1, MAP3K5 | MAPT 1279/4885KMT2A 784/4885TSHR 2596/4885 |
| US-20090286840-A1 | Thiophene-carboxamides useful as inhibitors of protein kinases | MAP3K20, ABL1, MAP3K5 | MAPT 1279/4885KMT2A 784/4885TSHR 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.